The Patent Finder

Oramed Ltd.

7 patents currently held · Updated Nov 21, 2026
1 more in force is now held by another company
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
3
Ending by 2030
Feb 2029
Next term end

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Nov 30, 2026
    The maintenance fee for Methods and Compositions for Oral Administration of Proteins (US 11,660,327) comes due Nov 30, 2026. Unpaid by Jun 1, 2027, it lapses early.
  • 1 fee due Jan 16, 2027
    The maintenance fee for Methods and compositions for oral administration of exenatide (US 10,350,162) comes due Jan 16, 2027. Unpaid by Jul 16, 2027, it lapses early.
  • 1 fee due Mar 3, 2027
    The maintenance fee for Methods and Compositions for Treating Diabetes (US 10,398,762) comes due Mar 3, 2027. Unpaid by Sep 3, 2027, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

  • 1 term has ended since Aug 23, 2026

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.

Showing 1 to 7 of 7

Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatus Expires Confidence
US 10,881,714Methods and Compositions for Oral Administration of Proteins
In force
 · High confidence
In forceHigh confidence
US 11,660,327Methods and Compositions for Oral Administration of Proteins
In force
 · High confidence
In forceHigh confidence
US 10,350,162Methods and compositions for oral administration of exenatide
In force
 · USPTO record
In forceUSPTO record
US 10,342,764Protease Inhibitor-Containing Compositions, Compositions Comprising Same, and Methods for Producing and Using Same
In force
 · High confidence
In forceHigh confidence
US 10,933,022Protease Inhibitor-Containing Compositions, Compositions Comprising Same, and Methods for Producing and Using Same
In force
 · Low confidence
In forceLow confidence
US 10,398,762Methods and Compositions for Treating Diabetes
In force
 · High confidence
In forceHigh confidence
US 10,967,051Methods and compositions for treating NAFLD, hepatic steatosis, and sequelae thereof
In force
 · USPTO record
In forceUSPTO record
Also on record, not counted in the 7: 1 patent in force now held by others · 2 lapsed for an unpaid fee · 7 ended at full term. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

2 pending · 5 abandoned · 6 no status recorded

Rows 11 to 13 of 13 are for members. The first 10 are on the company page.
Pro members see all 13 published applications.
Upgrade to Pro
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited